Lynn Stockwell - 18 Feb 2025 Form 4 Insider Report for Drugs Made In America Acquisition Corp. (DMAA)

Role: CEO and Exe. Chair of Board, Director, 10%+ Owner
Signature: /s/ Lynn Stockwell
Issuer symbol: DMAA
Transactions as of: 18 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 18 Feb 2025, 21:54:19 UTC
Previous filing: 04 Feb 2025
Next filing: 24 Sep 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DMAA	Ordinary shares	Purchase		+30,000	+0.72%		4,188,780	18 Feb 2025	See Footnotes	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAA	Rights to receive ordinary shares	Purchase		+30,000	+7.5%		430,000	18 Feb 2025	Ordinary shares	30,000		See Footnotes	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
F2	The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.

Content

Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.

The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.